EUVIMEDOpdag EUVIMED
Open access · CC BY-NC-ND 4.0

Clinicopathological and molecular characterization of KRAS wild‐type pancreatic ductal adenocarcinomas reveals precursor lesions with oncogenic mutations and fusions in RAS pathway genes

Kazuhiro Toriyama iD, Katsuhiro Masago, Noriko Shibata, Masataka Haneda, Takamichi Kuwahara, Seiji Natsume, Shota Kobayashi, Yasuko Fujita iD, Eiichi Sasaki iD, Kenji Yamao, Hiroki Kawashima, Yasuhiro Shimizu and 3 more

The Journal of Pathology · 2025

DOI: 10.1002/path.6432 ↗

At a glance

Journal article in The Journal of Pathology, 2025. Written by Kazuhiro Toriyama and 14 co-authors. Institution: Department of Pathology and Molecular Diagnostics, Aichi Cancer Center, Nagoya, Japan. Major MEDLINE topics: Carcinoma, Pancreatic Ductal, Pancreatic Neoplasms, Proto-Oncogene Proteins p21(ras), Mutation. 67 references. The full text is freely available (open access, CC BY-NC-ND 4.0). Funded by: Japan Society for the Promotion of Science.

AbstractSubjectsBibliografiske oplysningerCiteRelated studies

Abstract (original language)

Pancreatic ductal adenocarcinomas (PDACs) with wild‐type KRAS constitute a small fraction of PDACs, and these tumors were recently shown to harbor frequent actionable oncogenic mutations and fusions. However, the clinicopathological features of KRAS wild‐type PDAC have not been well studied. Additionally, precancerous lesions occurring in patients with KRAS wild‐type PDACs have rarely been characterized. Here, we investigated the clinicopathological characteristics and outcomes of 75 patients with KRAS wild‐type PDAC. Molecular analyses were performed in 40 patients using targeted DNA and whole‐exome sequencing and targeted RNA sequencing. We demonstrated that patients with metastatic PDAC with wild‐type KRAS were younger (median 59.5 years) than those with mutated KRAS (median 67 years, p < 0.000055). The wild‐type KRAS status was not a significant prognostic factor for metastatic disease. Molecularly, genes in the RAS pathway are frequently mutated or rearranged (46%, 16/35), including mutations in BRAF , NRAS , HRAS , EGFR , MAP2K1 , FGFR1 , FGFR3 and ERBB4 and fusions of FGFR2 ( FGFR2 :: CCDC147 , FGFR2 :: CAT , FGFR2 :: TXLNA ), ALK ( STRN :: ALK , EML4 :: ALK ), and BRAF ( TRIP11 :: BRAF ). Mismatch repair deficiency was identified in 10% (4/39) of patients. Potentially actionable alterations were identified frequently in KRAS wild‐type PDACs (30%, 12/40), in which nontubular‐type carcinomas were significantly enriched with actionable alterations compared with tubular adenocarcinomas [67% (6/9) versus 16% (5/31); p = 0.007]. Finally, we investigated the precursors of PDACs in 13 pancreatectomy specimens from patients with KRAS wild‐type PDAC. We identified three pancreatic intraepithelial neoplasias (PanINs) and two intraductal papillary mucinous neoplasms (IPMNs) harboring oncogenic fusions of ALK and BRAF and driver mutations in BRAF and AKT1 . This study suggests that in the context of unmutated KRAS , PDAC is driven by alternative oncogenic mutations or fusions of RAS pathway genes, which may be introduced during the early phase of tumorigenesis. © 2025 The Author(s). The Journal of Pathology published by John Wiley & Sons Ltd on behalf of The Pathological Society of Great Britain and Ireland.

Subjects

MeSH terms (MEDLINE)

Carcinoma, Pancreatic DuctalPancreatic NeoplasmsProto-Oncogene Proteins p21(ras)MutationPrecancerous ConditionsBiomarkers, TumorHumansAgedMaleFemaleMiddle AgedAged, 80 and overAdultSignal Transduction

Author keywords

IPMNPanINfusionnext‐generation sequencingpancreatic ductal adenocarcinomaprecursorwild‐type KRAS

Substances

Proto-Oncogene Proteins p21(ras)KRAS protein, humanBiomarkers, Tumor

Authors and institutions

  • Department of Pathology and Molecular Diagnostics, Aichi Cancer Center, Nagoya, Japan.
  • Department of Gastroenterology and Hepatology, Nagoya University Graduate School of Medicine, Nagoya, Japan.
  • Department of Gastroenterology, Aichi Cancer Center, Nagoya, Japan.
  • Department of Gastroenterological Surgery, Aichi Cancer Center, Nagoya, Japan.
  • Department of Gastroenterology, Narita Memorial Hospital, Toyohashi, Japan.
  • Department of Diagnostic Pathology, National Cancer Center Hospital, Tokyo, Japan.

ORCID profiles: Kazuhiro Toriyama, Yasuko Fujita, Eiichi Sasaki, Yasushi Yatabe, Waki Hosoda

Funding

  • Japan Society for the Promotion of Science

Cite

APA

Toriyama, K., Masago, K., Shibata, N., Haneda, M., Kuwahara, T., Natsume, S., Kobayashi, S., Fujita, Y., Sasaki, E., Yamao, K., Kawashima, H., Shimizu, Y., Hara, K., Yatabe, Y., & Hosoda, W. (2025). Clinicopathological and molecular characterization of KRAS wild‐type pancreatic ductal adenocarcinomas reveals precursor lesions with oncogenic mutations and fusions in RAS pathway genes. The Journal of Pathology. https://doi.org/10.1002/path.6432

Vancouver

Toriyama K, Masago K, Shibata N, Haneda M, Kuwahara T, Natsume S, et al. Clinicopathological and molecular characterization of KRAS wild‐type pancreatic ductal adenocarcinomas reveals precursor lesions with oncogenic mutations and fusions in RAS pathway genes. The Journal of Pathology. 2025. doi:10.1002/path.6432

BibTeX
@article{Toriyama2025,
  author = {Toriyama, Kazuhiro and Masago, Katsuhiro and Shibata, Noriko and Haneda, Masataka and Kuwahara, Takamichi and Natsume, Seiji and Kobayashi, Shota and Fujita, Yasuko and Sasaki, Eiichi and Yamao, Kenji and Kawashima, Hiroki and Shimizu, Yasuhiro and Hara, Kazuo and Yatabe, Yasushi and Hosoda, Waki},
  title = {Clinicopathological and molecular characterization of KRAS wild‐type pancreatic ductal adenocarcinomas reveals precursor lesions with oncogenic mutations and fusions in RAS pathway genes},
  journal = {The Journal of Pathology},
  year = {2025},
  doi = {10.1002/path.6432}
}
Start for free →